Effect of TGF-β1 antisense oligodeoxynucleotide on renal function in chronic renal failure rats

Acta Pharmacologica Sinica

Volumn 29, Issue 4, 2008, Pages 451-457

  Hiong, Law Chung ^a   Voon, Kiew Lik ^b   Abdullah, Nor Azizan ^a   Sattar, Munavvar A ^b   Rahman, Nazarina Abdul ^a   Khan, Abdul Hye ^b   Johns, Edward James ^c  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antisense oligodeoxynucleotides; Chronic renal failure; Renal function; Transforming growth factor 1

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PUROMYCIN; TRANSFORMING GROWTH FACTOR BETA1; ANTISENSE OLIGONUCLEOTIDE; INULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MALE; NONHUMAN; PROTEINURIA; RAT; ANIMAL; BLOOD; BLOOD FLOW; CHEMICALLY INDUCED DISORDER; GENETICS; INTERSTITIAL NEPHRITIS; KIDNEY; METABOLISM; NEPHRECTOMY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; VASCULARIZATION; WISTAR KYOTO RAT;

ANIMALS; GLOMERULAR FILTRATION RATE; INULIN; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; NEPHRECTOMY; NEPHRITIS, INTERSTITIAL; OLIGONUCLEOTIDES, ANTISENSE; ORGAN SIZE; PROTEINURIA; PUROMYCIN; RATS; RATS, INBRED WKY; REGIONAL BLOOD FLOW; TRANSFORMING GROWTH FACTOR BETA1;

EID: 41549087591     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00772.x     Document Type: Article

References (21)

1. Border WA, Noble NA. Transforming growth factor-β in tissue fibrosis. N Engl J Med1 1994 10: 1286 92.
2. Creely JJ, DiMari SJ, Howe AM, Haralson MA. Effects of transforming growth factor-β on collagen synthesis by normal rat kidney epithelial cells. Am J Pathol 1992 140: 45 55.
3. Michael Z, Frank S, Gerhard AM. Renal fibrosis: an update. Curr Opin Nephrol Hypertens 2001 10: 315 20.
4. O'Shea M, Miller SB, Finkel K, Hammerman MR. Roles of growth hormone and growth factors in the pathogenesis and treatment of kidney disease. Curr Opin Nephrol Hypertens 1993 2: 67 72.
5. Barnard JA, Lyons RM, Moses HL. The cell biology of transforming growth factor β. Biochim Biophys Acta 1990 1032: 79 87.
6. Lyons RM, Moses HL. Transforming growth factors and the regulation of cell proliferation. Eur J Biochem 1990 187: 467 73.
7. Roberts AB, Flanders KC, Heine UI, Jakowlew S, Kondaiah P, Kim SJ, et al. Transforming growth factor-β: multifunctional regulator of differentiation and development. Phil Trans R Soc Lond B 1990 327: 145 54.
8. Engelmeyer E, Van Goor H, Edwards DR, Diamond J. Differential mRNA expression of renal cortical tissue inhibits metallo-proteinases 1, 2 & 3 in experimental hydronephrosis. J Am Soc Nephrol 1995 5: 1675 83.
9. Okuda S, Languino LR, Ruoslahti E, Border WA. Elevated expression of transforming growth factor β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 1990 86: 453 62.
10. Sharma K, Ziyadeh FN. Emerging role of transforming growth factor-β in kidney diseases. Am J Physiol 1994 266: F829 42.
11. Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996 334: 316 8.
12. Neckers L, Whitesell L. Antisense technology: biological utility and practical consideration. Am J Physiol 1993 265: L1 12.
13. Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987 32: 691 9.
14. Akagi Y, Isaka Y, Arai M, Kaneko T, Tenaka M. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996 50: 148 55.
15. Armenia A, Munavvar AS, Abdullah NA, Helmi A, Johns EJ. The contribution of adrenoceptor subtype(s) in the renal vasculature of diabetic spontaneously hypertensive rats. Br J Pharmacol 2004 142: 719 26.
16. Hye Khan MA, Sattar MA, Abdullah NA, Johns EJ. Cisplatin cause altered renal hemodynamics in rats: role of augmented a-adrenergic responsiveness. Exp Toxicol Pathol 2007 59: 253 60.
17. Khan AH, Sattar MA, Abdullah NA, Johns EJ. Influence of cisplatin-induced renal failure on the alpha (1)-adrenoceptor subtype causing vasoconstriction in the kidney of the rat. Eur J Pharmacol 2007 569: 110 8.
18. Tofovic SP, Dubey R, Salah EM, Jackson EK. 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 2002 13: 2737 47.
19. Hestin D, Johns EJ. The influence of allopurinol on kidney haemodynamic and excretory responses to renal ischaemia in anaesthetised rats. Br J Pharmacol 1999 128: 255 61.
20. Yao Q, Qian JQ, Lin XH, Lindholm B. Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells. Int J Artif Organs 2004 27: 828 34.
21. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-β1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol (Renal Physiol) 2000 278: F628 34.